Injectable manufacturing specialist Symbiosis Pharmaceutical Services, located in Stirling, Scotland, has successfully completed an inspection from the UK's Medicines and Healthcare products Regulatory Agency (MHRA).
The contract manufacturing organisation (CMO) said it received no critical or major observations and this comes as various quality-related issues are affecting several other sterile manufacturing sites in the UK and US.
Symbiosis has been re-inspected and approved for the ongoing production of Investigational Medicinal Products (IMPs) for clinical trials. In a further boost to support the growth and development of the company, it received confirmation of continued authorisation for the GMP-manufacture of aseptically-filled licensed commercial products following initial approval of the commercial Manufacturer's/Importer's (MIA) licence last year.
The firm continues to thrive in light of increased demand for its services and due to industry trends such as the rising number of injectable drugs in development, increased biotech funding and more oncology and orphan drugs.
The commercial licence provides us with the opportunity to cater for small-scale commercial manufacturing projects
Colin MacKay, CEO at Symbiosis Pharmaceutical Services, said: 'Inspection failures at sterile filling sites have been a sensitive topic recently so it has been essential for us to maintain our focus on absolute GMP compliance, continual investment in meeting the latest emerging regulatory requirements and preserving our quality-driven business culture.
'Although our core business remains the sterile fill/finish of biologic and small molecule products into vials for clinical trials, the commercial licence provides us with the opportunity to cater for small-scale commercial manufacturing projects which the bigger CMOs see as unprofitable and therefore unattractive. Our operational flexibility and our cost base make those projects financially attractive both to us and to our clients.
'These abilities allow us to proactively support biotech and speciality pharmaceutical companies with products in niche markets and orphan indications that require relatively low volume or infrequent sterile filling. At the same time, it also gives us the potential to scale-up existing client projects which are successfully progressing through clinical trials towards market.'
Since 2011, Symbiosis has built a reputation for offering clients rapid access to sterile manufacturing slots and quick release of drug products to ensure tight clinical trial timelines are successfully met.
The CMO specialises in injectable medicines, which are either liquid or lyophilised formulations filled into vials. Its specialist capabilities include the ability to handle and fill antibodies, proteins, peptides, nucleic acids, cytotoxic, cytostatic and highly potent APIs including ADCs along with conventional small molecules.
